Prognostic factors including Ki-67 and p53 in Bacillus Calmette- Guérin-treated non-muscle-invasive bladder cancer: A prospective study

Urologia Internationalis

Volumn 90, Issue 2, 2013, Pages 184-190

  Oderda, Marco ^a   Ricceri, Fulvio ^a   Pisano, Francesca ^a   Fiorito, Chiara ^a   Gurioli, Alberto ^a   Casetta, Giovanni ^a   Zitella, Andrea ^a   Pacchioni, Donatella ^a   Gontero, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bacillus Calmette Gu rin; Ki 67; Non muscle invasive bladder cancer; p53; Prognostic factors

Indexed keywords

BCG VACCINE; KI 67 ANTIGEN; PROTEIN P53;

AGE; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CARCINOMA IN SITU; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; EPIDIDYMITIS; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; INFECTION; LOWER URINARY TRACT SYMPTOM; LUNG COMPLICATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATITIS; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SYSTEMIC DISEASE; TUMOR VOLUME;

ADULT; AGED; BCG VACCINE; CARCINOMA IN SITU; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84874465175     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000343431     Document Type: Article

References (40)

1. Hall MC, Chang S, Dalbagni G, et al: Guideline for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-2330
2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-314
3. Gontero P, Bohle A, Malmstrom P, O'Donnell MA, Oderda M, Sylvester R, Witjes F: The role of Bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57: 410-429
4. Sylvester R, Van der Meijden A, Lamm D: Intravesical Bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-1970
5. Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, Chopin DK: Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003; 43: 351-361
6. Herr HW, Dalbagni G: Defining Bacillus Calmette-Guérin refractory superficial bladder tumors. J Urol 2003; 169: 1706-1708
7. Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH: High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005: 66(suppl 1):90-107
8. Denzinger S, Fritsche H-M, Otto W, Blana A, Wieland W-F, Burger M: Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008; 53: 146-152
9. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE: Primary T1G3 bladder cancer: Organ-preserving approach or immediate cystectomy? J Urol 2004; 172: 70-75
10. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73-78
11. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al; Club Urológico Español de Tratamiento Oncológico (CUETO): Has a three-fold decreased dose of Bacillus Calmette-Guérin the same efficacy against the recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174: 1242-1247
12. Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance Bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-1129
13. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993; 85:53-59
14. Limas C, Bigler A, Bair R, Bernhart P, Reddy P: Proliferative activity of urothelial neoplasms: Comparison of BrdU in corporation, Ki-67 expression, and nucleolar organiser regions. J Clin Pathol 1993; 46: 159-165
15. Lacombe L, Dalbagni G, Zhang ZF, Cordon-Cardo C, Fair WR, Herr HW: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guérin therapy: Correlation to clinical outcome. J Clin Oncol 1996; 14: 2646-2652
16. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntanola P, Gimeno A, Blas M, Martinez-Pineiro JA: Prognostic factors in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin: Multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 992-1002
17. Takashi M, Wakai K, Hattori T, Furuhashi K, Ono Y, Ohshima S, Ohno Y: Multivariate evaluation of factors affecting recurrence, progression and survival in patients with superficial bladder cancer treated with intravesical Bacillus Calmette-Guérin (Tokyo 172 strain) therapy: Significance of concomitant carcinoma in situ. Int Urol Nephrol 2002; 33: 41-47
18. Andius P, Damm O, Holmang S: Prognostic factors in patients with carcinoma in situ treated with intravescical bacilli Calmette-Guérin. Scand J Urol Nephrol 2004; 38: 285-290
19. Davies JW, Sheth SI, Doviak MJ, Schellhammer PF: Superficial bladder carcinoma treated with Bacillus Calmette-Guérin: Progression-free and disease specific survival with 10-year minimum follow-up. J Urol 2002; 167: 494-501
20. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN: Longterm follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guérin: 18-year experience. Urology 2002; 59: 227-231
21. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC, Requena MJ, Montironi R: Prognostic factors in stage T1 grade 3 bladder cancer survival: The role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (Ki-67-MIB1). Eur Urol 2004; 45: 606-612
22. Marx J: How p53 suppresses cell growth. Science 1993; 262: 1644-1645
23. Muller PA, Vousden KH, Norman JC: P53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192: 209-218
24. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991; 351: 453-456
25. Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C, Muir GH, Tizzani A: Evaluation of p53 protein overexpression, Ki-67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000; 38: 287-296
26. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA: The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998; 29: 146-154
27. Ovesen H, Horn T, Steven K: Long-term efficacy of intravesical Bacillus of Calmette-Guérin for carcinoma in situ: Relationship of progression to histologic response and p53 nuclear accumulation. J Urol 1997; 157: 1655-1659
28. Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, Diez de Medina SG: Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin. Eur Urol 2004; 45: 475-482
29. Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP, Carrieri G: Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 2009; 29: 4201-4204
30. Lebret T, Becette V, Barbagelatta M, Herve JM, Gaudez F, Barre P: Correlation between p53 overexpression and response to Bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998; 159: 788-791
31. Peyromaure M, Weibing S, Sebe P, Verpillat P, Toublanc M, Dauge MC, Boccon-Gibod L, Ravery V: Prognostic value of p53 overexpression in T1G3 bladder tumours treated with Bacillus Calmette-Guérin therapy. Urology 2002; 59: 409-413
32. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, Teh M: Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-α. Cancer 2007; 109: 1097-1105
33. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-475, discussion 475-477
34. Sylvester RJ, Van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH: High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005; 66: 90-107
35. McShane LM, Aamodt R, Cordon-Cardo C, et al: Reproducibility of p53 immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-182
36. Gerdes J, Lemke H, Baisch H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715
37. Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, Nogueira-March JL: P53 and Ki-67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 2002; 41: 182-189
38. Lebret T, Becette V, Hervé JM, Molinié V, Barré P, Lugagne PM, Gentille A, Baglin AC, Botto H: Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000; 37: 654-659
39. Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC: Correlation and prognostic significance of p53, p21/WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumours treated with Bacillus Calmette-Guerin intravesical therapy. J Urol 1999; 161: 792-798
40. Zuiverloon TCM, Nieuweboer AJM, Vékony H, Kirkels WJ, Bangma CH, Zwarthoff EC: Markers predicting response to Bacillus Calmette-Guérin immunotherapy in highrisk bladder cancer patients: A systematic review. Eur Urol 2012; 61: 128-145